|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAP3K7 |
Gene summary for MAP3K7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAP3K7 | Gene ID | 6885 |
| Gene name | mitogen-activated protein kinase kinase kinase 7 | |
| Gene Alias | CSCF | |
| Cytomap | 6q15 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | O43318 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6885 | MAP3K7 | LZE4T | Human | Esophagus | ESCC | 1.54e-07 | 2.39e-01 | 0.0811 |
| 6885 | MAP3K7 | LZE7T | Human | Esophagus | ESCC | 5.56e-09 | 3.83e-01 | 0.0667 |
| 6885 | MAP3K7 | LZE8T | Human | Esophagus | ESCC | 1.02e-04 | 1.33e-01 | 0.067 |
| 6885 | MAP3K7 | LZE20T | Human | Esophagus | ESCC | 3.39e-04 | 1.62e-01 | 0.0662 |
| 6885 | MAP3K7 | LZE24T | Human | Esophagus | ESCC | 1.15e-13 | 3.60e-01 | 0.0596 |
| 6885 | MAP3K7 | LZE21T | Human | Esophagus | ESCC | 3.07e-02 | 2.44e-01 | 0.0655 |
| 6885 | MAP3K7 | P2T-E | Human | Esophagus | ESCC | 2.65e-18 | 3.59e-01 | 0.1177 |
| 6885 | MAP3K7 | P4T-E | Human | Esophagus | ESCC | 2.15e-13 | 2.74e-01 | 0.1323 |
| 6885 | MAP3K7 | P5T-E | Human | Esophagus | ESCC | 5.59e-12 | 1.35e-01 | 0.1327 |
| 6885 | MAP3K7 | P8T-E | Human | Esophagus | ESCC | 1.07e-13 | 2.81e-01 | 0.0889 |
| 6885 | MAP3K7 | P9T-E | Human | Esophagus | ESCC | 6.14e-04 | 1.43e-01 | 0.1131 |
| 6885 | MAP3K7 | P10T-E | Human | Esophagus | ESCC | 6.82e-20 | 3.22e-01 | 0.116 |
| 6885 | MAP3K7 | P11T-E | Human | Esophagus | ESCC | 2.60e-15 | 5.18e-01 | 0.1426 |
| 6885 | MAP3K7 | P12T-E | Human | Esophagus | ESCC | 8.10e-15 | 3.96e-01 | 0.1122 |
| 6885 | MAP3K7 | P15T-E | Human | Esophagus | ESCC | 1.07e-16 | 3.27e-01 | 0.1149 |
| 6885 | MAP3K7 | P16T-E | Human | Esophagus | ESCC | 9.28e-25 | 5.40e-01 | 0.1153 |
| 6885 | MAP3K7 | P17T-E | Human | Esophagus | ESCC | 2.88e-06 | 3.51e-01 | 0.1278 |
| 6885 | MAP3K7 | P19T-E | Human | Esophagus | ESCC | 4.06e-09 | 4.13e-01 | 0.1662 |
| 6885 | MAP3K7 | P20T-E | Human | Esophagus | ESCC | 3.32e-06 | 1.06e-01 | 0.1124 |
| 6885 | MAP3K7 | P21T-E | Human | Esophagus | ESCC | 4.24e-19 | 4.80e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00064752 | Liver | HCC | internal protein amino acid acetylation | 107/7958 | 160/18723 | 3.77e-10 | 1.23e-08 | 107 |
| GO:001624111 | Liver | HCC | regulation of macroautophagy | 96/7958 | 141/18723 | 6.82e-10 | 2.14e-08 | 96 |
| GO:00183932 | Liver | HCC | internal peptidyl-lysine acetylation | 105/7958 | 158/18723 | 9.48e-10 | 2.90e-08 | 105 |
| GO:00165732 | Liver | HCC | histone acetylation | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
| GO:00027533 | Liver | HCC | cytoplasmic pattern recognition receptor signaling pathway | 46/7958 | 60/18723 | 7.37e-08 | 1.49e-06 | 46 |
| GO:00022211 | Liver | HCC | pattern recognition receptor signaling pathway | 107/7958 | 172/18723 | 1.37e-07 | 2.58e-06 | 107 |
| GO:00105082 | Liver | HCC | positive regulation of autophagy | 81/7958 | 124/18723 | 2.34e-07 | 4.17e-06 | 81 |
| GO:000724912 | Liver | HCC | I-kappaB kinase/NF-kappaB signaling | 156/7958 | 281/18723 | 6.66e-06 | 8.00e-05 | 156 |
| GO:004312312 | Liver | HCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 108/7958 | 186/18723 | 1.28e-05 | 1.43e-04 | 108 |
| GO:003109822 | Liver | HCC | stress-activated protein kinase signaling cascade | 138/7958 | 247/18723 | 1.43e-05 | 1.57e-04 | 138 |
| GO:005140322 | Liver | HCC | stress-activated MAPK cascade | 134/7958 | 239/18723 | 1.50e-05 | 1.64e-04 | 134 |
| GO:004312212 | Liver | HCC | regulation of I-kappaB kinase/NF-kappaB signaling | 138/7958 | 249/18723 | 2.47e-05 | 2.58e-04 | 138 |
| GO:007155921 | Liver | HCC | response to transforming growth factor beta | 141/7958 | 256/18723 | 3.08e-05 | 3.16e-04 | 141 |
| GO:007156021 | Liver | HCC | cellular response to transforming growth factor beta stimulus | 137/7958 | 250/18723 | 5.47e-05 | 5.14e-04 | 137 |
| GO:007190021 | Liver | HCC | regulation of protein serine/threonine kinase activity | 189/7958 | 359/18723 | 5.97e-05 | 5.47e-04 | 189 |
| GO:00028312 | Liver | HCC | regulation of response to biotic stimulus | 173/7958 | 327/18723 | 8.55e-05 | 7.48e-04 | 173 |
| GO:0016239 | Liver | HCC | positive regulation of macroautophagy | 41/7958 | 63/18723 | 2.47e-04 | 1.84e-03 | 41 |
| GO:00705551 | Liver | HCC | response to interleukin-1 | 80/7958 | 143/18723 | 7.95e-04 | 4.77e-03 | 80 |
| GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
| GO:000717921 | Liver | HCC | transforming growth factor beta receptor signaling pathway | 106/7958 | 198/18723 | 1.09e-03 | 6.23e-03 | 106 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
| hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
| hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
| hsa05170210 | Esophagus | ESCC | Human immunodeficiency virus 1 infection | 147/4205 | 212/8465 | 3.37e-09 | 3.53e-08 | 1.81e-08 | 147 |
| hsa0513526 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
| hsa05171211 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
| hsa0414010 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
| hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
| hsa051619 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
| hsa0465727 | Esophagus | ESCC | IL-17 signaling pathway | 66/4205 | 94/8465 | 3.93e-05 | 1.75e-04 | 8.99e-05 | 66 |
| hsa0514525 | Esophagus | ESCC | Toxoplasmosis | 76/4205 | 112/8465 | 6.83e-05 | 2.90e-04 | 1.48e-04 | 76 |
| hsa0415210 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
| hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
| hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
| hsa040645 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
| hsa046607 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAP3K7 | SNV | Missense_Mutation | rs758224984 | c.821G>A | p.Arg274His | p.R274H | O43318 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MAP3K7 | SNV | Missense_Mutation | c.919G>A | p.Glu307Lys | p.E307K | O43318 | protein_coding | tolerated(0.22) | benign(0.013) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| MAP3K7 | SNV | Missense_Mutation | novel | c.1745N>G | p.Ser582Cys | p.S582C | O43318 | protein_coding | tolerated(0.08) | possibly_damaging(0.908) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| MAP3K7 | insertion | Frame_Shift_Ins | novel | c.1670_1671insAAATAAACAA | p.Asp557GlufsTer5 | p.D557Efs*5 | O43318 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MAP3K7 | SNV | Missense_Mutation | c.217N>T | p.Ala73Ser | p.A73S | O43318 | protein_coding | deleterious(0) | benign(0.176) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MAP3K7 | SNV | Missense_Mutation | c.49N>A | p.Glu17Lys | p.E17K | O43318 | protein_coding | tolerated_low_confidence(0.15) | benign(0.017) | TCGA-AZ-6599-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MAP3K7 | SNV | Missense_Mutation | c.1754A>G | p.Tyr585Cys | p.Y585C | O43318 | protein_coding | tolerated(0.27) | benign(0) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MAP3K7 | SNV | Missense_Mutation | rs762121500 | c.1237N>T | p.Arg413Cys | p.R413C | O43318 | protein_coding | deleterious(0.05) | probably_damaging(0.973) | TCGA-F4-6807-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | CR |
| MAP3K7 | SNV | Missense_Mutation | novel | c.197N>G | p.Glu66Gly | p.E66G | O43318 | protein_coding | deleterious(0) | benign(0.25) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MAP3K7 | SNV | Missense_Mutation | c.673C>T | p.Arg225Cys | p.R225C | O43318 | protein_coding | deleterious(0.02) | probably_damaging(0.963) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6885 | MAP3K7 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 329968393 | ||
| 6885 | MAP3K7 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 223366077 | RGB-286638 | |
| 6885 | MAP3K7 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 348353658 | ||
| 6885 | MAP3K7 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 249565754 | ||
| 6885 | MAP3K7 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 348353615 | ||
| 6885 | MAP3K7 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 249565876 | ||
| 6885 | MAP3K7 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 249565757 | CHEMBL1077979 | |
| 6885 | MAP3K7 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 348353659 | ||
| 6885 | MAP3K7 | ENZYME, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 249565869 | CEP-11981 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |